Related Experiment Videos
Role of indomethacin in ductus closure: an update evaluation
S M Douidar1, J Richardson, W R Snodgrass
1University of Texas Medical Branch, Department of Pediatrics, Galveston.
Insights
Indomethacin effectively closes patent ductus arteriosus (PDA) in premature infants, reducing mortality and bronchopulmonary dysplasia. This drug therapy is a safer, noninvasive alternative to surgery for preterm infants.
Area of Science:
- Neonatal Medicine
- Pediatric Pharmacology
Background:
- Patent ductus arteriosus (PDA) poses a significant challenge in premature infants.
- Pharmacological closure is a key therapeutic strategy.
Purpose of the Study:
- To evaluate the efficacy of indomethacin for PDA closure in preterm infants.
- To explore the role of furosemide in mitigating indomethacin's side effects.
Main Methods:
- Pharmacological intervention using indomethacin, a prostaglandin synthetase inhibitor.
- Consideration of pharmacokinetic characteristics for optimal drug levels.
- Co-administration with furosemide to manage renal side effects.
Main Results:
- Indomethacin demonstrates effectiveness in closing PDA.
- Potential reduction in mortality and morbidity, including bronchopulmonary dysplasia, in very low birth weight infants.
- Furosemide may attenuate transient renal side effects.
Conclusions:
- Indomethacin is a noninvasive, cost-effective, and safer therapy for PDA closure compared to surgical ligation.
- Understanding drug pharmacokinetics is crucial for therapeutic success in preterm neonates.
Abstract:
Patent ductus arteriosus (PDA) in premature infants is a current challenge to pediatricians. Pharmacological closure of PDA with indomethacin, a prostaglandin synthetase inhibitor is an effective drug therapy, along with usual medical treatment. Administration of indomethacin may decrease mortality and morbidity (e.g. bronchopulmonary dysplasia) among very small premature infants (less than 1,000 g). Co-administration of furosemide with indomethacin may lessen the transient renal side effects of indomethacin. The therapeutic efficacy of indomethacin in closure of PDA depends largely on understanding and manipulation of the pharmacokinetic characteristics of the drug in preterm infants. Maintaining a therapeutic level of the drug in plasma is essential to achieve an optimal therapeutic response. Compared to surgical ligation, indomethacin is a noninvasive, less expensive and safer therapy for ductus closure.